In the STEP-1 trial of 1,961 adults (Wilding and colleagues, Once-Weekly Semaglutide in Adults with Overweight or Obesity, New England Journal of Medicine, 2021), participants on semaglutide 2.4 mg lost an average of 14.9 percent of their body weight at 68 weeks, compared to 2.4 percent on placebo
In the circulation, about 75% of LC occurs in the free state, 15% as ALC, and the remaining 10% as esters of carnitine with other acids (e.g., propionyl-L-carnitine) [64]
If you have a BMI of 22 or higher, you may be an eligible candidate for the GLP-1 Microdose Protocol
Always consult a healthcare provider before exceeding this
A clinical study on modified growth hormone releasing factor (CJC-1295) demonstrated sustained increases in GH and IGF-1 levels following repeated dosing with a favorable safety profile, supporting the use of consistent dosing over multi-week protocols